Concerns about a type of NSAID called COX - 2 inhibitors peaked in 2004 when the drug Vioxx was withdrawn from the market — a decision steeped in scandal because
manufacturer Merck & Co had initially
hidden data that would reveal the drug's cardiovascular
risks.